At 16 weeks, many saw significant itch relief; in a follow-up analysis, results were seen as soon as 48 hours. At 16 and 48 weeks, many saw clear or almost clear skin. Results may vary.

Not an actual patient.

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO^® (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone.

Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO.

Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. You should not receive a live vaccine right before or during treatment with NEMLUVIO.

Adverse Events: Most common side effects of NEMLUVIO include: headache, joint pain, hives (itchy red rash or wheals) and muscle aches.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information including Patient Information for NEMLUVIO.

©2025 Galderma Laboratories, L.P. All Rights Reserved.

NEMLUVIO is a registered trademark of Galderma.

US-NAD-2500004 04/25